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vey by a group of respected UK anesthetists demonstrated a low incidence of serious 
complications, related to the pharmacology and dose of the drugs. However, a current 

concerns include the physical stability of the emulsion when remifentanil is mixed 
with propofol; changes in drug concentration over time; nonuniform mixing of propo-
fol and remifentanil; the risk of bacterial contamination; and the potential for drug 
administration errors. Propofol and remifentanil have markedly different pharma-
cokinetic profiles. When remifentanil is mixed with propofol and delivered as a tar-

but passively follows the variable infusion rates calculated by the syringe driver to 
deliver predicted plasma or effect-site concentrations of propofol. The pharmacoki-
netic consequences can be illustrated using pharmacokinetic modeling similar to that 
-

rapid increase and peak in remifentanil concentration that risks apnea, bradycardia, 
and hypotension, especially with higher concentrations of remifentanil. The faster 
decline in remifentanil concentration with falling propofol concentrations risks inad-
equate narcosis and unwanted responses to surgical stimuli. Remifentanil delivery is 
inflexible and dosing cannot be adjusted to the clinical need and responses of indi-

propofol and remifentanil creates a new, unlicensed drug and the person mixing takes 

of a mixed propofol-remifentanil infusion suffered a critical incident or actual harm, 
the clinician's practice may come under scrutiny and criticism, potentially involving a 
legal challenge and the Medical Regulator.
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-
pental caused by injecting succinylcholine into an un-flushed can-

follow in any number of unlicensed drug mixtures with succeeding 
generations repeating the mistakes of their predecessors.1,2 Naïvely, 
anesthetists may assume that the absence of crystals or of any other 
changes visible to the naked eye implies compatibility but this is not 
necessarily the case. Ever since it first became available for use in 
clinical practice, anesthetists have experimented with the addition 

is presented as a sterile oil in water emulsion, the addition of diluents 
and other drugs poses several problems. The opacity of the propofol 
emulsion likely conceals any evidence of crystallized drug, and im-
portant changes in the lipid emulsion characteristics are not visible 
to the naked eye.
The most common additive is lidocaine, which reduces pain on 
injection.-
tanil or ketamine to propofol, because they wish to infuse propo-
fol and the added drug, using a single infusion pump.5-7 Reasons for 
using a single pump to infuse two or more drugs range from conve-
nience to a lack of resources.
              
among pediatric anesthetists, often using a mixture of propofol and 
remifentanil.8 There are several reasons why pediatric anesthetists 

not always readily available, even in high resource countries, and 
administration of remifentanil from a separate syringe and line in-
creases cost. Pediatric surgery operating schedules commonly list 
several short duration procedures in quick succession, and mixing of 
  
small children, it is desirable to limit administered fluid volumes, and 
mixing remifentanil in the propofol emulsion reduces the volume of 
carrier fluid.
          
                
pediatric anesthetists, but recommended against this practice, par-
ticularly when propofol is administered by target-controlled infusion 
9  The reasons for caution quoted in the guideline are largely 
consistent with those mentioned in a previous editorial on mixing,10 
      -
tempt to demonstrate the safety of mixing propofol and remifen-
tanil, a group of respected UK pediatric anesthetists performed a 
service evaluation of the safety and efficacy of this technique in 
almost 900 patients, and presented their findings in this journal.11

                    
-





159 anesthetics. The majority were minor and expected, such as 
movement or coughing, whereas the incidence of events that were 
serious, related to the pharmacology of the drugs but unexpected 

patients, the 95% confidence interval for this proportion is approxi-
mately 1%-2.8%. Complications were more likely to occur when the 

Does this result show that it is acceptable for you to try out this 

as acceptable and defensible if a body of respected colleagues uses 
it, and this is certainly the case here. Do these data prove that the 
technique is safe? This is a tough question to answer. The confidence 
interval mentioned above certainly falls well below the published in-

              12     
safety is usually only regarded as proven once a drug or technique 
has been studied in thousands of patients, and under similar condi-
tions. The investigators are all highly experienced experts, and they 
present the results of an observational study in what is essentially 

your own hospital, then it would be worthwhile spending some time 
in the company of an expert to learn the technique.
Moreover, this study simply looked at the incidence of clinical 
                    
should be borne in mind include physicochemical stability and 
compatibility of the mixture, other safety aspects including bacte-
rial contamination and drug error, differences in pharmacokinetics 
of the two drugs which can cause specific problems when infusion 
rates are high or low, and finally medicolegal matters. Some of these 
have been discussed previously,10 but we feel that their importance 
is sufficient to warrant a reprise.
 |

                  
coalesce producing fewer but larger ones. Ultimately visible “cream-
ing” may occur. Historically, this was visible in glass bottles of milk 
where over time fatty droplets coalesced and then floated to the top 
of the aqueous component, forming a layer of cream.
The original  commercial  propofol formulation, Diprivan®  
            
          
       
-

the egg yolk lecithin.

lecithin support a stable negative electrostatic charge, the zeta po-
tential which causes droplets to repel each other thereby maintain-
ing their dispersal and subsequently the stability of the emulsion.
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
propofol emulsion provides a charge carrier allowing dispersal of the 
zeta potential, increasing droplet size and potentially precipitating 








Stewart and colleagues studied the stability of propofol and 
remifentanil concentrations when the drugs are mixed, for 





               -
tanil concentrations decreased significantly over time (by 8% and 

admixtures, the remifentanil concentrations remained stable. The 
                 
bags, where the propofol concentrations declined slowly over time, 
presumably because of interaction between the propofol and the 

   11  the majority of clinicians used admix-
   
remifentanil concentration declines over time, but which is associ-
ated with a lower incidence of adverse events. Given the fact that 
 




When two drugs are mixed and then infused, the infusion rates of 
each drug will only be and remain consistent with expectations if 

that this is not the case for propofol and remifentanil.16  They added 
remifentanil to propofol 1% in a vertically mounted syringe to pro-
                
  
            
higher in the uppermost portions of the mixture. For propofol, the 
gradient was in the opposite direction. This effect was most pro-

drugs, the concentrations at the top and bottom of the mixture were 
-
fol, respectively. Their results showed that in addition to the large 





is less of a problem with a horizontally mounted syringe, this has not 
been evaluated in a published study.
 |
Propofol emulsions are sterile but strongly support bacterial growth 
-
                   
-
tion and subsequent administration, led to very serious and some-
times catastrophic clusters of infections in the United States.17,18 
Since 1996, propofol formulations sold in the United States have 

18 European anes-
thetists rely on hand hygiene and aseptic technique.
When remifentanil is added to propofol, it must first be dissolved, 
as it is presented as a powder, and this step and the subsequent addi-
tion to the propofol present opportunities for contamination.
 |

Propofol/opioid mixtures are visibly indistinguishable from the un-
adulterated injectate thereby generating opportunities for drug ad-
             
labeling of drugs prepared in operating theaters, these are not uni-
versally followed. Further, the additive increases the net volume of 
the mixture thereby decreasing the concentration of propofol in the 
                




are added to propofol solutions.
 |
                
                    
follows:
Under current UK and European legislation, ex-
cept in very restricted circumstances, mixing drugs 
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together, where one is not a vehicle for the adminis-
tration of the other, creates an unlicensed medicine. 
The person undertaking this preparation, unless  
            
licence.19
The above implies, in theory at least, that the mixer becomes 
  
the consequences of its administration. This is a daunting prospect, 
albeit a theoretical one. Furthermore, as these mixtures constitute 
unlicensed medicines, and/or off-label use of licensed medicines, 
this adds to the responsibilities of the clinician. Not only does the 
UK General Medical Council advise doctors against using drugs in 
a nonstandard and unapproved manner, it also specifically advises 




The pharmacokinetics of propofol and remifentanil can be de-
scribed by  multi-compartment mammillary models.21   
these models contain some  assumptions which  are demonstra-
bly invalid (eg, that mixing within the central compartment is in-
         
                22  
these models are ubiquitous in anesthesia teaching and research 
        we can turn to them 
to describe the likely consequences of co-administering propofol 
and remifentanil, whose pharmacokinetics and pharmacodynam-
          11  the responsible anesthetists 
 
     




the calculations, we have assumed a propofol concentration of 

the mix. For each figure, we first used Stanpump software1 to calcu-
late the infusion rates required for the simulated plasma target propo-
fol concentration profile, with the Paedfusor model parameters for a 
            
purposes, we also estimated the effect-site propofol concentration  
using a ke0  of 0.26/min.
25 We then programmed Stanpump with the 
Eleveld PK/PD model parameters for remifentanil for this child,26 to 
estimate the resulting estimated remifentanil plasma and effect-site 
concentrations arising. Figure 1 shows that when the infusion is 
             
temporary rise in remifentanil plasma and effect-site concentrations. 










for propofol and remifentanil, respectively. Predicted effect-site remifentanil concentration overshoots when the infusion is started
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appropriate concentration during painful procedures (such as laryn-

most patients will not breathe spontaneously, but will still move in 







Eleveld kinetic sets were used for propofol and remifentanil, respectively. Predicted effect-site remifentanil concentration overshoots 





pharmacokinetic sets were used for propofol and remifentanil, respectively. Staging the approach to the initial target plasma concentration 
of propofol attenuates the relative overdosage of remifentanil
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clinicians should remember that the initial bolus is bigger with ef-
                  
pump is used to administer an effect-site targeted infusion of a 






of the mixture to stop temporarily, the faster kinetics of remifentanil  
dictate that the remifentanil concentrations will fall proportionately 
            
that the estimated effect-site remifentanil concentrations will fall to 
                     -
                 
remifentanil plasma and effect-site concentrations than propofol con-
centrations, with declines to inadequate remifentanil concentrations.
Since the kinetics of remifentanil are linear, the achieved 
plasma and effect-site concentrations can be extrapolated from 
the above simulations. Mixtures containing less remifentanil will 
likely result in inadequate plasma and effect-site concentrations, 
and this will be exacerbated by the instability of remifentanil over 
  
the other hand, more concentrated mixtures will result in very 
   
which adverse effects are expected (bradycardia and hypoten-

invariable.
Feedback from clinicians and simulation suggest that the impact 





anil mixtures are probably in good company, they should remember 
that this technique has several dangers, theoretical or otherwise, as 
described above. Clinicians should be aware that if they practice this 
technique, and a patient under their care suffers a critical incident, it 
is likely that their practice will come under close scrutiny. While they 
could offer as a defense the fact that there is a body of reasonable 
and experienced clinicians who practice this technique, it is unlikely 
that they will find support from health and regulatory bodies (such as 


             -


                 
has received honoraria from The Medicines Company (Parsippany, 
              
            
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
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